A systematic review and network meta-analysis focused on alosetron, eluxadoline, ramosetron, and rifaximin in adult patients who had irritable bowel syndrome (IBS) with diarrhea or mixed stool.
Decompensation-free survival improved in patients with cirrhosis and portal hypertension who received beta-blockers versus placebo, largely due to a decrease in ascites.
While the findings highlight the importance of surveillance colonoscopies, improvements in endoscopic detection of dysplasia and polyps alone are unlikely to explain the decrease in the hazard ratio of CRC in
There was no significant difference in upper GI events between a pantoprazole group and a placebo group, although pantoprazole was associated with significantly reduced bleeding of gastroduodenal lesions, an industry-funded study found.
The primary outcome of the retrospective cohort study was postcolonoscopy colorectal cancer within three years, defined as colorectal cancer diagnosed within six and 36 months after negative findings on index colonoscopy.
Patients with ulcerative colitis treated with 5-aminosalicylates who require escalation to anti-tumor necrosis factor-alpha (anti-TNF) therapy may be able to safely discontinue the first drug.
Monotherapy for inflammatory bowel disease (IBD) with an immunosuppressive agent was associated with a lower risk of serious infection than a tumor necrosis factor (TNF) antagonist alone or an anti-TNF plus an immunosuppressive agent, according to a
The guideline focuses on oral and topical 5-aminosalicylic acid medications, rectal corticosteroids, and oral budesonide in patients with mild to moderate disease.
Among other guidance, the American College of Gastroenterology recommends anticoagulation for all patients without cirrhosis who have acute symptomatic portal vein thrombosis or mesenteric vein thrombosis in the absence of any contraindication.
The increase primarily occurred among people who reported drug use or homelessness.